{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:43:34Z","timestamp":1771332214169,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.vph.2014.03.001","type":"journal-article","created":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T00:38:22Z","timestamp":1395448702000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Bemiparin, an effective and safe low molecular weight heparin: A review"],"prefix":"10.1016","volume":"62","author":[{"given":"Marco Matteo","family":"Ciccone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Corbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel Ernesto","family":"Corrales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Kareem","family":"Al-Momen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annapaola","family":"Zito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Scicchitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2014.03.001_bb0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/1158581-S0-000000000-00000","article-title":"Bemiparin: pharmacological profile","volume":"70","author":"S\u00e1nchez-Ferrer","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.vph.2014.03.001_bb0010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/14779072.6.6.793","article-title":"Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism","volume":"6","author":"Mart\u00ednez-Gonz\u00e1lez","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.vph.2014.03.001_bb0015","first-page":"S5","article-title":"European consensus statement on the prevention of venous thromboembolism. European Consensus Conference, Windsor, U.K., November, 1991","volume":"4","author":"Haas","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.vph.2014.03.001_bb0020","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1055\/s-0037-1616243","article-title":"The epidemiology of venous thromboembolism in the community","volume":"86","author":"Heit","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2014.03.001_bb0025","first-page":"423A","article-title":"Prevention of venous thromboembolism in surgical patients by low-dose heparin: prepared by the Council on Thrombosis of the American Heart Association","volume":"55","year":"1977","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2014.03.001_bb0030","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1055\/s-0037-1613574","article-title":"Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis","volume":"89","author":"Kakkar","year":"2003","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.vph.2014.03.001_bb0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4155\/fmc.11.185","article-title":"Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics","volume":"4","author":"Masuko","year":"2012","journal-title":"Future Med Chem"},{"issue":"3","key":"10.1016\/j.vph.2014.03.001_bb0040","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.thromres.2011.11.008","article-title":"Old and new heparins","volume":"129","author":"Cosmi","year":"2012","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.vph.2014.03.001_bb0045","first-page":"807","article-title":"Heparin and low-molecular-weight heparin","volume":"99","author":"Gray","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2014.03.001_bb0050","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.thromres.2011.03.001","article-title":"A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin","volume":"128","author":"Jeske","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2014.03.001_bb0055","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.thromres.2012.03.013","article-title":"Differential Effects of Fondaparinux and Bemiparin on Angiogenic and Vasculogenesis-like processes","volume":"130","author":"Da Pozzo","year":"2012","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.vph.2014.03.001_bb0060","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.thromres.2011.05.005","article-title":"Antiangiogenic activities of bemiparin sodium, enoxaparin sodium, nadroparin calcium and tinzaparin sodium","volume":"128","author":"Dogan","year":"2011","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.vph.2014.03.001_bb0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/07357907.2010.543217","article-title":"LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells","volume":"29","author":"Vignoli","year":"2011","journal-title":"Cancer Invest"},{"issue":"2\u20133","key":"10.1016\/j.vph.2014.03.001_bb0070","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ejphar.2008.11.042","article-title":"Bemiparin improves the total antioxidant status in plasma","volume":"602","author":"Garc\u00eda-de-la-Asunci\u00f3n","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.vph.2014.03.001_bb0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1254\/jphs.08018SC","article-title":"Effects of bemiparin, dalteparin, and unfractionated heparin on platelet interaction with human subendothelium under flow conditions","volume":"107","author":"Gonz\u00e1lez-Correa","year":"2008","journal-title":"J Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.vph.2014.03.001_bb0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.thromres.2011.03.001","article-title":"A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin","volume":"128","author":"Jeske","year":"2011","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.vph.2014.03.001_bb0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/107602960200800109","article-title":"Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium","volume":"8","author":"P\u00e9rez-Ruiz","year":"2002","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"10.1016\/j.vph.2014.03.001_bb0090","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1055\/s-0037-1616761","article-title":"Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro","volume":"86","author":"Westmuckett","year":"2001","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.vph.2014.03.001_bb0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00001721-199803000-00004","article-title":"Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, bemiparin, at therapeutic subcutaneous doses","volume":"9","author":"Falkon","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"10.1016\/j.vph.2014.03.001_bb0100","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1538-7836.2007.02477.x","article-title":"Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation","volume":"5","author":"Gerotziafas","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"1\u20133","key":"10.1016\/j.vph.2014.03.001_bb0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejphar.2004.11.014","article-title":"Effects of bemiparin on airway responses to antigen in sensitized Brown\u2013Norway rats","volume":"507","author":"Suchankova","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.vph.2014.03.001_bb0110","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2133.2007.08007.x","article-title":"Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight","volume":"157","author":"Grims","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.vph.2014.03.001_bb0115","first-page":"744","article-title":"Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. EMRO1 (Grupo Fstudio Multicintrico RO-11)","volume":"43","author":"Moreno Gonzalez","year":"1996","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.vph.2014.03.001_bb0120","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1538-7836.2003.00142.x","article-title":"Bemiparin Study Group in Knee Arthroplasty. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial","volume":"1","author":"Navarro-Quilis","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2014.03.001_bb0125","first-page":"258","article-title":"Prophylactic antithrombotic therapy after orthopedic surgery with bemiparin, a second-generation low molecular weight heparin","volume":"48","author":"Plan\u00e8s","year":"2001","journal-title":"Rev Esp Anestesiol Reanim"},{"key":"10.1016\/j.vph.2014.03.001_bb0130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1076029607303962","article-title":"Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice","volume":"14","author":"Otero-Fern\u00e1ndez","year":"2008","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.vph.2014.03.001_bb0135","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00402-006-0239-x","article-title":"Bemiparin 6 Hours After Surgery Study Group. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6h after knee or hip replacement surgery","volume":"127","author":"Abad","year":"2007","journal-title":"Arch Orthop Trauma Surg"},{"key":"10.1016\/j.vph.2014.03.001_bb0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/1158584-S0-000000000-00000","article-title":"Clinical experience with bemiparin","volume":"70","author":"Abad Rico","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.vph.2014.03.001_bb0145","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1111\/j.1538-7836.2006.02171.x","article-title":"Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of venous thromboembolism in patients with transient risk factors in standard clinical practice: the FLEBUS study","volume":"4","author":"Lecumberri","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2014.03.001_bb0150","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1368-5031.2006.00947.x","article-title":"ESFERA Investigators. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study","volume":"60","author":"Santamar\u00eda","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.vph.2014.03.001_bb0155","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.vph.2014.03.001_bb0160","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1160\/TH03-03-0152","article-title":"Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures","volume":"90","author":"White","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2014.03.001_bb0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/1158586-S0-000000000-00000","article-title":"New frontiers with bemiparin: use in special populations","volume":"70","author":"Fontcuberta","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.vph.2014.03.001_bb0170","first-page":"165","article-title":"Use of anticoagulants in elderly patients: practical recommendations","volume":"4","author":"Robert-Ebadi","year":"2009","journal-title":"Clin Interv Aging"},{"issue":"3","key":"10.1016\/j.vph.2014.03.001_bb0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11586730-000000000-00000","article-title":"Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment","volume":"28","author":"Samama","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1016\/j.vph.2014.03.001_bb0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11586730-000000000-00000","article-title":"Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment","volume":"28","author":"Samama","year":"2011","journal-title":"Drugs Aging"},{"issue":"2 Suppl.","key":"10.1016\/j.vph.2014.03.001_bb0185","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.vph.2014.03.001_bb0190","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ahj.2010.06.001","article-title":"Fibrinogen and left ventricular myocardial systolic function: the multi-ethnic study of atherosclerosis","volume":"160","author":"Yan","year":"2010","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.vph.2014.03.001_bb0195","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1751-7133.2010.00148.x","article-title":"Venous thromboembolic disease in congestive heart failure","volume":"16","author":"Dean","year":"2010","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.vph.2014.03.001_bb0200","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1067\/mhj.2002.121268","article-title":"Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure","volume":"143","author":"De Lorenzo","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.vph.2014.03.001_bb0205","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0212-6567(03)70729-X","article-title":"Triple-blind clinical trial with placebo control to evaluate the efficacy of a heparin of low molecular weight (bemiparin) for treating slow-responding ulcers in diabetic foot in primary care","volume":"31","author":"Rull\u00e1n","year":"2003","journal-title":"Aten Primaria"},{"key":"10.1016\/j.vph.2014.03.001_bb0210","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1742-1241.2006.01081.x","article-title":"Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy","volume":"61","author":"Constans","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.vph.2014.03.001_bb0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/1158585-S0-000000000-00000","article-title":"Bemiparin in oncology","volume":"70","author":"Monreal Bosch","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.vph.2014.03.001_bb0220","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","article-title":"A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer","volume":"2","author":"Altinbas","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2014.03.001_bb0225","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1538-7836.2010.03892.x","article-title":"Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study","volume":"8","author":"Kakkar","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2014.03.001_bb0230","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer","volume":"346","author":"Bergqvist","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2014.03.001_bb0235","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/j.1538-7836.2006.02153.x","article-title":"Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study","volume":"4","author":"Rasmussen","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2014.03.001_bb0240","doi-asserted-by":"crossref","first-page":"333","DOI":"10.5435\/JAAOS-20-06-333","article-title":"American College of Chest Physicians evidence-based guidelines for venous thromboembolic prophylaxis: the guideline wars are over","volume":"20","author":"Lieberman","year":"2012","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.vph.2014.03.001_bb0290","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijsu.2006.07.005","article-title":"Bemiparin Cooperative Study Group in Surgery for Cancer. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice","volume":"5","author":"Balibrea","year":"2007","journal-title":"Int J Surg"},{"issue":"1","key":"10.1016\/j.vph.2014.03.001_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2013.06.007","article-title":"Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer","volume":"88","author":"Walenga","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.vph.2014.03.001_bb0255","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-013-1014-9","article-title":"Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis","author":"Phan","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.vph.2014.03.001_bb0260","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jso.20728","article-title":"Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer","volume":"95","author":"Icli","year":"2007","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.vph.2014.03.001_bb0265","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1161\/01.ATV.0000090671.56682.D7","article-title":"Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight","volume":"23","author":"Khorana","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2014.03.001_bb0270","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.thromres.2007.06.015","article-title":"Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin","volume":"121","author":"Marchetti","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2014.03.001_bb0275","first-page":"17","article-title":"Pharmacoeconomic analysis of prophylaxis for thromboembolic disease in hip replacement patients [in Spanish]","volume":"1","author":"Bonal","year":"2000","journal-title":"Rev Espa Farmacoecon"},{"key":"10.1016\/j.vph.2014.03.001_bb0280","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2165\/00019053-200422130-00006","article-title":"Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery","volume":"22","author":"Honorato","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vph.2014.03.001_bb0285","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00019053-200624010-00007","article-title":"Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis","volume":"24","author":"G\u00f3mez-Outes","year":"2006","journal-title":"Pharmacoeconomics"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114000548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114000548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T19:58:20Z","timestamp":1565294300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189114000548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1537189114000548"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2014.03.001","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bemiparin, an effective and safe low molecular weight heparin: A review","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2014.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}